Minerva Neurosciences’ Clinical Data Featured at The American College of Neuropsychopharmacology Annual Meeting
05. Dezember 2016 08:00 ET
|
Minerva Neurosciences, Inc.
Oral presentation highlights specific improvements in negative symptoms and cognition observed in schizophrenic patients treated with MIN-101 in Phase IIB trial Data also presented from Phase IIA...